膦甲酸钠治疗慢性乙型重型病毒性肝炎65例

目的:探讨膦甲酸钠治疗慢性重型乙型肝炎的疗效。方法:128例重型乙型肝炎患者随机分为对照组63例,给予治疗常规治疗;治疗组65例,在常规治疗基础上加用膦甲酸钠治疗,膦甲酸钠注射液2.4g/250m l,2次/d,疗程28d。结果:肝功能复常率、HBVDNA的阴转率治疗组优于对照组(P<0.001)。治疗组肝性脑病、感染、肝肾综合征发生率分别为23.1%(15/65)、15.4%(10/65)、29.2%(19/65)明显低于对照组46.0%(29/63)、33.3%(21/63)、47.6%(30/63)差异有统计学意义(P<0.001)。病死率:治疗组29.2%(19/65),显著低于对照组52.3%(33/63)(P<0.01)。结论:在基础保肝支持治疗同时,及时应用膦甲酸钠能显著提高慢性乙型重型肝炎的抢救成功率。

Foscarnet sodium for treatment of 65 patients with chronic severe hepatitis B

Objective: To investigate the effectiveness of foscarnet sodium in the treatment of patients with chronic severe hepatitis B.Methods: 128 patients were randomly put into a conventional supporting treatment control group and a foscarnet sodium treatment group.In the latter,65 patients were given foscarnet sodium injection besides the support care which was also given to the control group.Results: The rate of death in the foscarnet sodium treatment group was significantly lower than control group(29.2% vs 52.3%,P<0.01).There was significant difference between two group in the recovery of liver function and HBVDNA negative rate.In addition,the rate of hepatic coma(23.1% vs 46.0% P<0.01),infection(15.4% vs33.3% P<0.0 5),and hepatic kidney failure(29.2% vs47.6% P<0.0 5) in the foscarnet sodium treatment group were significant lower than control group.Conclusions: Our results suggest that foscarnet sodium administration with conventional supporting treatment has a good effect in patients with chronic severe hepatitis B.